Home/Dyne Therapeutics/Jeffrey M. Statland, MD

JM

Jeffrey M. Statland, MD

Scientific Advisory Board Member

Dyne Therapeutics

Therapeutic Areas

Neuromuscular Diseases Rare Diseases Genetic Disorders

Dyne Therapeutics Pipeline

Drug	Indication	Phase
DYNE-101	Myotonic Dystrophy Type 1 (DM1)	Phase 1/2
DYNE-251	Duchenne Muscular Dystrophy (DMD) amenable to exon 51 skipping	Phase 1/2
DYNE-301	Facioscapulohumeral Muscular Dystrophy (FSHD)	Phase 1/2

Leadership Team at Dyne Therapeutics

Joshua T. Brumm

President, Chief Executive Officer, and Director

Susanna G. High

Chief Operating Officer

Oxana B. Corjuc, CPA

Chief Financial Officer

John T. McHutchison, AO, MD

Chief Medical Officer

Carlo Rizzuto, PhD

Chief Scientific Officer

Jennifer K. Yates, J.D.

Chief Legal Officer and Corporate Secretary

Wildon R. Farwell, MD, MPH

Chief Development Officer

Jason P. Rhodes

Chairman of the Board

Catherine A. Sohn, PharmD

Lawrence M. Alleva

View full Dyne Therapeutics profile